India Develops Smart Cancer Drug RK-251

Recently, Indian scientists developed RK-251, a “smart” cancer drug designed to activate mainly inside cancer cells, potentially reducing damage to healthy tissues compared with conventional chemotherapy.

Key Points

Targeted Activation: RK-251 remains relatively inactive in normal tissues and activates under conditions found inside cancer cells.
ROS-Based Mechanism: Cancer cells often contain high levels of reactive oxygen species (ROS), which trigger RK-251’s activation.
NBDHEX Release: Once activated, RK-251 releases the anticancer compound NBDHEX inside cancer cells.
Cancer Survival Proteins: NBDHEX targets proteins that help cancer cells survive and develop treatment resistance.
Preclinical Results: RK-251 showed strong activity against triple-negative breast cancer cells.
Lower Toxicity: Experiments indicated substantially lower effects on healthy cells compared with its anticancer activity.